Quantinno Capital Management LP Has $1.55 Million Holdings in Guardant Health, Inc. $GH

Quantinno Capital Management LP raised its stake in Guardant Health, Inc. (NASDAQ:GH) by 218.1% in the first quarter, Holdings Channel.com reports. The firm owned 16,831 shares of the company’s stock after acquiring an additional 11,540 shares during the period. Quantinno Capital Management LP’s holdings in Guardant Health were worth $1,555,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health in the fourth quarter valued at about $27,000. Elyxium Wealth LLC acquired a new stake in Guardant Health during the fourth quarter worth about $35,000. Parallel Advisors LLC grew its position in Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after buying an additional 219 shares in the last quarter. EFG International AG bought a new position in Guardant Health during the fourth quarter valued at about $41,000. Finally, Ascentis Independent Advisors bought a new position in Guardant Health during the first quarter valued at about $38,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Trading Up 0.0%

NASDAQ GH opened at $165.11 on Thursday. The stock’s 50 day moving average is $149.24 and its two-hundred day moving average is $116.27. The company has a market capitalization of $22.16 billion, a price-to-earnings ratio of -47.31 and a beta of 1.60. Guardant Health, Inc. has a 1-year low of $53.40 and a 1-year high of $176.58.

Wall Street Analysts Forecast Growth

GH has been the subject of a number of research reports. TD Cowen raised their price objective on Guardant Health from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Barclays boosted their price objective on Guardant Health from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Mizuho upped their target price on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $210.00 target price on shares of Guardant Health in a research report on Friday, July 31st. Finally, Evercore reiterated an “outperform” rating and set a $200.00 price target on shares of Guardant Health in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $183.78.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CEO Helmy Eltoukhy sold 100,000 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $126.30, for a total transaction of $12,630,000.00. Following the completion of the transaction, the chief executive officer directly owned 2,012,919 shares in the company, valued at $254,231,669.70. This represents a 4.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John G. Saia sold 20,000 shares of Guardant Health stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total value of $2,130,200.00. Following the transaction, the insider directly owned 45,950 shares of the company’s stock, valued at approximately $4,894,134.50. The trade was a 30.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 738,050 shares of company stock worth $98,859,427 over the last three months. 5.60% of the stock is currently owned by insiders.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.